• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Physiol Lung Cell Mol Physiol . Immunoglobulin Deficiency as an Indicator of Disease Severity in Patients with COVID-19

tetano

Editor, Senior Moderator
Am J Physiol Lung Cell Mol Physiol


. 2020 Nov 25.
doi: 10.1152/ajplung.00359.2020. Online ahead of print.
Immunoglobulin Deficiency as an Indicator of Disease Severity in Patients with COVID-19


Faeq Husain-Syed[SUP] 1 [/SUP], Istv?n Vad?sz[SUP] 2 [/SUP], Jochen Wilhelm[SUP] 3 [/SUP], Hans-Dieter Walmrath[SUP] 4 [/SUP], Werner Seeger[SUP] 5 [/SUP], Horst-Walter Birk[SUP] 6 [/SUP], Birgit Jennert[SUP] 7 [/SUP], Hartmut Dietrich[SUP] 7 [/SUP], Susanne Herold[SUP] 8 [/SUP], Janina Trauth[SUP] 9 [/SUP], Khodr Tello[SUP] 5 [/SUP], Michael Sander[SUP] 10 [/SUP], Rory E Morty[SUP] 11 [/SUP], Heiko Slanina[SUP] 12 [/SUP], Christian G Sch?ttler[SUP] 12 [/SUP], John Ziebuhr[SUP] 13 [/SUP], Shadi Kassoumeh[SUP] 14 [/SUP], Claudio Ronco[SUP] 15 [/SUP], Fiorenza Ferrari[SUP] 16 [/SUP], Klaus Warnatz[SUP] 17 [/SUP], Klaus Stahl[SUP] 18 [/SUP], Benjamin Seeliger[SUP] 19 [/SUP], Marius M Hoeper[SUP] 20 [/SUP], Tobias Welte[SUP] 21 [/SUP], Sascha David[SUP] 22 [/SUP]



Affiliations

Abstract

Despite the pandemic status of COVID-19, there is limited information about host risk factors and treatment beyond supportive care. Immunoglobulin G (IgG) could be a potential treatment target. Our aim was to determine the incidence of IgG deficiency and associated risk factors in a cohort of 62 critical ill COVID-19 patients admitted to two German ICUs (72.6% male, median age: 61 years). 13 (21.0%) of the patients displayed IgG deficiency (IgG <7 g/L) at baseline (predominant for the IgG1, IgG2, and IgG4 subclasses). IgG-deficient patients had worse measures of clinical disease severity than those with normal IgG levels (shorter duration from disease onset to ICU admission, lower ratio of PaO[SUB]2[/SUB] to FiO[SUB]2[/SUB], higher Sequential Organ Failure Assessment score, and higher levels of ferritin, neutrophil-to-lymphocyte ratio and serum creatinine). IgG-deficient patients were also more likely to have sustained lower levels of lymphocyte counts and higher levels of ferritin throughout the hospital stay. Furthermore, IgG-deficient patients compared to those with normal IgG levels displayed higher rates of acute kidney injury (76.9% vs. 26.5%; p=0.005) and death (46.2% vs. 14.3%; p=0.012), longer ICU (28 [6-48] vs. 12 [3-18] days; p=0.012) and hospital length of stay (30 [22-50] vs. 18 [9-24] days; p=0.004). Multivariable logistic regression showed increasing odds of 90-day overall mortality associated with IgG-deficiency (OR 12.8, 95% CI 1.5-108.4; p=0.019). IgG deficiency might be common in critically ill COVID-19 patients, and warrants investigation as both a marker of disease severity as well as a potential therapeutic target.

Keywords: Cytokine release syndrome; Immunodysregulation; Respiratory failure; Severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom